| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1040131238 |
| P356 | DOI | 10.1038/NATURE03389 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nature03389 |
| P698 | PubMed publication ID | 15815632 |
| P5875 | ResearchGate publication ID | 7920254 |
| P50 | author | Sabine Steffens | Q63357516 |
| Claire Arnaud | Q43091097 | ||
| P2093 | author name string | Andreas Zimmer | |
| Fabienne Burger | |||
| François Mach | |||
| Graziano Pelli | |||
| Meliha Karsak | |||
| Jean-Louis Frossard | |||
| Christian Staub | |||
| Niels R Veillard | |||
| P2860 | cites work | ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree | Q72689998 |
| Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression | Q72690003 | ||
| Aortic recruitment of blood lymphocytes is most pronounced in early stages of lesion formation in apolipoprotein-E-deficient mice | Q73355679 | ||
| T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2 influence on lesion formation | Q74211034 | ||
| Leukocyte-endothelial cell interactions are enhanced in dermal postcapillary venules of MRL/fas(lpr) (lupus-prone) mice: roles of P- and E-selectin | Q77995917 | ||
| Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system | Q80884566 | ||
| Inflammation in atherosclerosis | Q29547428 | ||
| Inflammation and atherosclerosis | Q29615203 | ||
| T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions | Q35143874 | ||
| The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis | Q35208754 | ||
| The cannabinoid system and immune modulation | Q35213813 | ||
| Lymphocytes are important in early atherosclerosis | Q36072647 | ||
| Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells | Q40987444 | ||
| Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway | Q41742529 | ||
| Biphasic effects of anandamide | Q43332781 | ||
| Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor | Q43503403 | ||
| The pharmacological activity of inhalation exposure to marijuana smoke in mice | Q43619986 | ||
| In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice | Q43669472 | ||
| Differential effects of delta 9-THC on spatial reference and working memory in mice | Q43761949 | ||
| Delta(9)-THC, 11-OH-Delta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people | Q43812487 | ||
| Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells | Q44225647 | ||
| Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice | Q44324625 | ||
| Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells | Q44590321 | ||
| Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis | Q44929830 | ||
| Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice | Q45086363 | ||
| The effects of orally administered delta 9-tetrahydrocannabinol in man on mood and performance measures: a dose-response study. | Q51168893 | ||
| P2507 | corrigendum / erratum | Erratum: Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice | Q61386215 |
| P433 | issue | 7034 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoids | Q422936 |
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 782-786 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice | |
| P478 | volume | 434 |
| Q93356097 | A Systematic Review of Marijuana Use and Outcomes in Patients with Myocardial Infarction |
| Q51057792 | A design strategy for small molecule-based targeted MRI contrast agents: their application for detection of atherosclerotic plaques. |
| Q94595206 | A high-quality reference genome of wild Cannabis sativa |
| Q35803402 | A synergistic interaction of 17-β-estradiol with specific cannabinoid receptor type 2 antagonist/inverse agonist on proliferation activity in primary human osteoblasts |
| Q24647198 | AM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitors |
| Q41429518 | Activation of cannabinoid receptor 2 enhances osteogenic differentiation of bone marrow derived mesenchymal stem cells |
| Q36838206 | Activation of cannabinoid receptor 2 inhibits experimental cystitis |
| Q28302804 | Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects |
| Q34588703 | An exploratory prospective study of marijuana use and mortality following acute myocardial infarction |
| Q43190361 | Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action? |
| Q26750399 | Anticancer mechanisms of cannabinoids |
| Q36993599 | Appetite and metabolic effects of ghrelin and cannabinoids: involvement of AMP-activated protein kinase |
| Q37306185 | Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study |
| Q52615780 | Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. |
| Q58197660 | Atherosclerosis is an inflammatory disease |
| Q33687100 | Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells |
| Q40001901 | Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration |
| Q24645478 | Beta-caryophyllene is a dietary cannabinoid |
| Q34626997 | Bone mineral density and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study |
| Q34992040 | CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages |
| Q34098258 | CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model |
| Q34733645 | CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways |
| Q36416330 | CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration |
| Q24643591 | CB2 receptor-mediated migration of immune cells: it can go either way |
| Q34657057 | CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion |
| Q47202996 | Ca2+-dependent potassium channels and cannabinoid signaling in the endothelium of apolipoprotein E knockout mice before plaque formation |
| Q33564023 | Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration |
| Q36927185 | Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis |
| Q43145354 | Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? |
| Q33464957 | Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis |
| Q84514529 | Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice |
| Q35029725 | Cannabinoid Receptor 2 Deficiency in Haematopoietic cells Aggravates Early Atherosclerosis in LDL Receptor Deficient Mice. |
| Q36089227 | Cannabinoid Receptor Type 2 (CB2) Dependent and Independent Effects of WIN55,212-2 on Atherosclerosis in Ldlr-null Mice |
| Q27000762 | Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal |
| Q91869538 | Cannabinoid receptor 2 deficiency exacerbates inflammation and neutrophil recruitment |
| Q64084242 | Cannabinoid receptor 2 deletion deteriorates myocardial infarction through the down-regulation of AMPK-mTOR-p70S6K signaling-mediated autophagy |
| Q33889311 | Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice |
| Q37120339 | Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease |
| Q37174735 | Cannabinoid receptor CB2 protects against balloon-induced neointima formation |
| Q37546194 | Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies? |
| Q34238768 | Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice |
| Q36416382 | Cannabinoid receptors and the regulation of bone mass |
| Q36734955 | Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases |
| Q36416368 | Cannabinoid receptors in acute and chronic complications of atherosclerosis. |
| Q39163671 | Cannabinoid signaling in health and disease |
| Q34098271 | Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells |
| Q33847549 | Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy |
| Q92097842 | Cannabinoids and Cardiovascular System |
| Q37978806 | Cannabinoids and atherosclerotic coronary heart disease |
| Q37563061 | Cannabinoids and the skeleton: from marijuana to reversal of bone loss |
| Q36052772 | Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions |
| Q24633884 | Cannabinoids in health and disease |
| Q90102164 | Cannabinoids, the Heart of the Matter |
| Q28395270 | Cannabis exposure as an interactive cardiovascular risk factor and accelerant of organismal ageing: a longitudinal study |
| Q33865109 | Carboxylesterases: Dual roles in lipid and pesticide metabolism |
| Q35837289 | Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse. |
| Q47804552 | Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly |
| Q56764637 | Chapter 11 Recent Advances in the Discovery of CB2 Selective Agonists |
| Q51774126 | Characterization and in vitro and in vivo testing of CB2-receptor- and NGAL-targeted paramagnetic micelles for molecular MRI of vulnerable atherosclerotic plaque. |
| Q38429080 | Characterization of Structurally Novel G Protein Biased CB1 Agonists: Implications for Drug Development |
| Q35099114 | Chemical Atherogenesis: Role of Endogenous and Exogenous Poisons in Disease Development |
| Q24634161 | Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain |
| Q53658218 | Cumulative Lifetime Marijuana Use and Incident Cardiovascular Disease in Middle Age: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. |
| Q38832242 | Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. |
| Q34530470 | De Novo Lipogenesis Products and Endogenous Lipokines |
| Q36426806 | Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase |
| Q34173104 | Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III. |
| Q38995052 | Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice |
| Q54572183 | Deficiency of type 1 cannabinoid receptors worsens acute heart failure induced by pressure overload in mice. |
| Q91674480 | Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB2 R Ligands |
| Q41140253 | Dietary Njavara rice bran oil reduces experimentally induced hypercholesterolaemia by regulating genes involved in lipid metabolism |
| Q82678385 | Does cannabis hold the key to treating cardiometabolic disease? |
| Q37421147 | Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk |
| Q47373403 | Effect of rimonabant on weight reduction and cardiovascular risk |
| Q46973009 | Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils |
| Q92487916 | Efficacy of Terpenoid in Attenuating Aortic Atherosclerosis in Apolipoprotein-E Deficient Mice: A Meta-Analysis of Animal Studies |
| Q53245546 | Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. |
| Q24647850 | Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation |
| Q37230665 | Emerging strategies for exploiting cannabinoid receptor agonists as medicines |
| Q30473707 | Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects |
| Q38135915 | Endocannabinoid system as a potential mechanism for n-3 long-chain polyunsaturated fatty acid mediated cardiovascular protection |
| Q38593139 | Endocannabinoids and Cancer. |
| Q36416372 | Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning |
| Q38593133 | Endocannabinoids and the Cardiovascular System in Health and Disease |
| Q36358723 | Endocannabinoids and the haematological system |
| Q37412217 | Endocannabinoids and the heart. |
| Q30368944 | Endocannabinoids, blood pressure and the human heart. |
| Q61386215 | Erratum: Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice |
| Q38072055 | Evidence for the involvement of cannabinoid receptors' polymorphisms in the pathophysiology of human diseases |
| Q46059840 | Formation of B and T cell subsets require the cannabinoid receptor CB2. |
| Q89657326 | Functional lncRNA-miRNA-mRNA networks in rabbit carotid atherosclerosis |
| Q35094180 | GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils |
| Q38593120 | Genetic Manipulation of the Endocannabinoid System |
| Q36938493 | Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors |
| Q35028750 | Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS |
| Q48099573 | In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans |
| Q30981876 | Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2 |
| Q46938785 | Induction of preferential chemotaxis of unstimulated B-lymphocytes by 2-arachidonoylglycerol in immunized mice |
| Q38255902 | Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment. |
| Q39062398 | Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis. |
| Q34651059 | Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression |
| Q46118910 | Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice |
| Q34698887 | Insulin resistance and atherosclerosis |
| Q24634125 | Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain |
| Q46480886 | Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States. |
| Q54431377 | Investigations into the hypothesis of transgenic cannabis. |
| Q24633122 | Is lipid signaling through cannabinoid 2 receptors part of a protective system? |
| Q35501238 | Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists |
| Q24654730 | Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay |
| Q24629571 | Marijuana use and long-term mortality among survivors of acute myocardial infarction |
| Q44500279 | Mechanism of platelet activation induced by endocannabinoids in blood and plasma |
| Q36933683 | Modulating the endocannabinoid system in human health and disease--successes and failures |
| Q37601380 | Modulation of Human Peripheral Blood Mononuclear Cell Signaling by Medicinal Cannabinoids |
| Q90322108 | Modulation of the Oxidative Stress and Lipid Peroxidation by Endocannabinoids and Their Lipid Analogues |
| Q36940347 | Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations |
| Q40509301 | Molecular MRI of Inflammation in Atherosclerosis |
| Q39141240 | Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling |
| Q36438873 | Monoglyceride lipase deficiency modulates endocannabinoid signaling and improves plaque stability in ApoE-knockout mice |
| Q92633111 | Myocardial maladaptation to pressure overload in CB2 receptor-deficient mice |
| Q36576558 | New anti-inflammatory agents to reduce atherosclerosis |
| Q36659848 | New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors |
| Q34624990 | Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells |
| Q61813934 | Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation |
| Q38678763 | Oxyradical Stress, Endocannabinoids, and Atherosclerosis |
| Q37572785 | Oxysterols in heart failure |
| Q46840844 | PARP1 is required for adhesion molecule expression in atherogenesis |
| Q24536360 | Peripheral cannabinoid receptor, CB2, regulates bone mass |
| Q37669645 | Peripheral metabolic effects of endocannabinoids and cannabinoid receptor blockade |
| Q34155467 | Peroxisomal and microsomal lipid pathways associated with resistance to hepatic steatosis and reduced pro-inflammatory state |
| Q46426162 | Pharmacology: marijuana and your heart |
| Q37461480 | Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis? |
| Q36496316 | Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases |
| Q81242873 | Potential role of CB2 receptors in Cannabis smokers with chronic hepatitis C |
| Q49600632 | Preface to DMR special edition 'Cannabinoid receptors and ligands: therapeutic drug development and abuse potential'. |
| Q35672413 | Primary Macrophage Chemotaxis Induced by Cannabinoid Receptor 2 Agonists Occurs Independently of the CB2 Receptor. |
| Q39959642 | Production of the endocannabinoids anandamide and 2-arachidonoylglycerol by endothelial progenitor cells. |
| Q30506148 | Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. |
| Q35179985 | Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy |
| Q38158190 | Recent advances in LC-MS/MS analysis of Δ(9)-tetrahydrocannabinol and its metabolites in biological matrices |
| Q36477479 | Recent progress in cannabinoid research |
| Q34309880 | Recreational drug use and risk of Kaposi's sarcoma in HIV- and HHV-8-coinfected homosexual men. |
| Q34471868 | Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. |
| Q34054143 | Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2. |
| Q46202541 | Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages |
| Q24673335 | Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers |
| Q90732163 | Systematic Affinity Purification Coupled to Mass Spectrometry Identified p62 as Part of the Cannabinoid Receptor CB2 Interactome |
| Q33604098 | Targeted zwitterionic near infrared fluorescent probe for improved imaging of type 2 cannabinoid receptors |
| Q36346915 | Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies |
| Q33655394 | Targeting cannabinoid signaling for peritoneal dialysis-induced oxidative stress and fibrosis |
| Q24623282 | Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities |
| Q24650098 | The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset |
| Q28066700 | The CB2 receptor and its role as a regulator of inflammation |
| Q35937792 | The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. |
| Q24651712 | The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration |
| Q33993080 | The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages |
| Q24643876 | The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin |
| Q37439386 | The emerging role of the endocannabinoid system in cardiovascular disease |
| Q36904442 | The endocannabinoid network: insight into the regulation of the neuroendocrine and metabolic systems |
| Q35951992 | The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications |
| Q34626755 | The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use. |
| Q35193292 | The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings |
| Q24648473 | The endocannabinoid system as an emerging target of pharmacotherapy |
| Q46204521 | The endocannabinoid system in cardiovascular function: novel insights and clinical implications |
| Q36381416 | The endocannabinoid system: current pharmacological research and therapeutic possibilities |
| Q35122796 | The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications |
| Q24648765 | The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans |
| Q36416347 | The peripheral cannabinoid receptor knockout mice: an update |
| Q37143578 | The role of the endocannabinoid system in atherosclerosis. |
| Q36341688 | The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids |
| Q53270045 | The time window of MRI of murine atherosclerotic plaques after administration of CB2 receptor targeted micelles: inter-scan variability and relation between plaque signal intensity increase and gadolinium content of inversion recovery prepared versu |
| Q40361574 | Towards a therapeutic use of selective CB2 cannabinoid receptor ligands for atherosclerosis |
| Q84066889 | Towards the use of cannabinoids as antitumour agents |
| Q42904836 | Translating Endocannabinoid Biology into Clinical Practice: Cannabidiol for Stroke Prevention |
| Q37330515 | Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction in hypercholesterolemic mice. |
| Q54753732 | Understanding the molecular aspects of tetrahydrocannabinol and cannabidiol as antioxidants. |
| Q35915645 | Update on the role of cannabinoid receptors after ischemic stroke |
| Q47120802 | Δ9-Tetrahydrocannabinol Prevents Cardiovascular Dysfunction in STZ-Diabetic Wistar-Kyoto Rats. |
| Q35854652 | β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner |
| Q61386215 | Erratum: Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice | main subject | P921 |
Search more.